Results 201 to 210 of about 581,882 (243)

Prospective randomised double‐blind trial: holmium laser lithotripsy with vs without Moses™ 2.0

open access: yesBJU International, Volume 138, Issue 6, Page 1104-1114, December 2026.
Objective To assess the effect of Moses™ 2.0 (Lumenis Be Ltd., Yokneam Illit, Israel; Boston Scientific, Marlborough, MA, USA) for lithotripsy of renal stones of 8–20 mm in diameter on operative time, surgeon workload, and retropulsion. Subjects/Patients and Methods In our multicentre, randomised, double‐blind clinical trial, patients were randomised 1:
Kimberly A. Maciolek   +19 more
wiley   +1 more source

Predictive utility of a simple cranial magnetic resonance imaging score at term‐equivalent age for cerebral palsy

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 12, Page 1729-1739, December 2026.
This study evaluated the Total Abnormality Score (TAS) from cMRI at term‐equivalent age as a predictor of cerebral palsy (CP) in 137 infants born preterm or with low birthweight. Infants who developed CP had significantly higher TAS values (median 11 vs 2), with a TAS cut‐off of 9.5 demonstrating high sensitivity (88.9%) and specificity (91.4%) for CP ...
Anne‐Kathrin Dathe   +6 more
wiley   +1 more source

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11702-11709, December 2026.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre   +6 more
wiley   +1 more source

Gastrointestinal complications of cocaine use: a narrative literature review. [PDF]

open access: yesFront Gastroenterol (Lausanne)
Qasim A   +4 more
europepmc   +1 more source

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

open access: yesJournal of Internal Medicine, Volume 300, Issue 6, Page 758-778, December 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2289-2302, November 2026.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy